A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Status
Active
Cancer Type
Unknown Primary
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01733004
Protocol IDs
MM-141-01-01-01 (primary)
Study Sponsor
Merrimack Pharmaceuticals, Incorporated

Summary

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.